CLINICAL_TRIALS
trial_result
· 2025-02-27
Clinical Trial Update: JSP191 (briquilimab) in Subjects with LR-MDS [Phase 1]
Summary
The Phase 1 trial of JSP191 (briquilimab) in patients with lower-risk myelodysplastic syndrome has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Jasper Therapeutics, Inc. | Conditions: Lower-risk Myelodysplastic Syndrome | Phase 1 | Status: TERMINATED